Le Lézard
Classified in: Health
Subject: AWD

Varian Wins "Best After-Sales Service Performance Award for Radiotherapy Products" in China


PALO ALTO, Calif., April 18, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it received the "Best After-Sales Service Performance Award for Radiotherapy Products" in the annual Chinese Medical Devices Industry Data and After-Sales Service Survey.

The survey, which has been conducted annually for the last eight years, is organized by China Medical Equipment magazine, published by People's Medical Publishing House Co., Ltd., Health News, as well as several industry associations including the Medical Engineering Branch of the Chinese Medical Association and the Clinical Engineering Branch of the Chinese Medical Doctors Association. It is one of the most influential medical industry performance evaluations conducted in China.

In 2017, the survey included respondents from 34 provinces and 1,700 hospitals. More than 10,000 clinical engineering professionals across China responded to the survey, which covered equipment quality, maintenance quality, price, training, efficiency, and service attitude. Various brands of medical equipment were ranked according to after-sales service indicators such as market share, user satisfaction, recommendation preference, core competitiveness, and a six-dimensional comprehensive satisfaction score.

The goal of the survey organizers was to understand and evaluate customer satisfaction with the after-sales service provided by medical technology manufacturers, and to provide those companies with information that can help them standardize and improve the quality of their after-sales service programs. In the area of radiotherapy technology, Varian was ranked number one in after-sales service efficiency, after-sales service attitude, and product quality.

"We are very pleased that Varian's products and after-sales services received this award and are thankful to our customers in China for the recognition," said Dr. Zhang Xiao, Varian's vice president and managing director of the Greater China region. "This award will also encourage us to continue innovating to provide clinicians and patients in China with superior and efficient services."

About Varian
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact

Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact

J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

 

SOURCE Varian


These press releases may also interest you

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...



News published on and distributed by: